Emily Bodnar, an analyst from H.C. Wainwright, has initiated a new Buy rating on vTv Therapeutics (VTVT).
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Emily Bodnar’s rating is based on the promising potential of vTv Therapeutics’ lead asset, cadisegliatin, which targets a significant unmet need in the treatment of Type 1 diabetes (T1D). The drug has shown positive efficacy and safety results in the SimpliciT1 study, leading to the FDA granting it Breakthrough Therapy Designation. This designation highlights the high unmet need and the differentiated data supporting cadisegliatin’s potential.
Furthermore, cadisegliatin’s unique molecular design addresses previous safety challenges faced by glucokinase activators (GKAs), such as hypoglycemia and hepatotoxicity, by ensuring selective activation in the liver and maintaining natural glucose regulation. The lifting of the FDA’s clinical hold on the Phase 3 CATT1 study further bolsters confidence in the drug’s development, allowing the company to proceed with patient enrollment and increasing the likelihood of successful outcomes. These factors collectively underpin Bodnar’s Buy rating for vTv Therapeutics’ stock.